CHEMOMAB THERAPEUTICS LTD (CMMB)

US16385C1045 - ADR

0.839  +0.03 (+3.58%)

After market: 0.84 +0 (+0.12%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

CHEMOMAB THERAPEUTICS LTD

NASDAQ:CMMB (5/10/2024, 7:00:01 PM)

After market: 0.84 +0 (+0.12%)

0.839

+0.03 (+3.58%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap11.92M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CMMB Daily chart

Company Profile

Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. The firm specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Company Info

CHEMOMAB THERAPEUTICS LTD

Kiryat Atidim, Building 7

TEL AVIV-YAFO 02139

CEO: Neil Cohen

Employees: 37

Website: https://www.chemomab.com/

CMMB News

News Image2 days ago - InvestorPlaceCMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q1 2024

Chemomab Therapeutics just reported results for the first quarter of 2024.

News Image3 days ago - Chemomab TherapeuticsChemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
News Image3 days ago - Chemomab TherapeuticsChemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Chemomab reported on major progress in Q1 2024, including that it is on track to report Phase 2 PSC topline data at midyear 2024...

News Image4 days ago - Chemomab TherapeuticsChemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
News Image10 days ago - Chemomab TherapeuticsChemomab Therapeutics to Present at 2024 Aegis Virtual Conference
News Image10 days ago - Chemomab TherapeuticsChemomab Therapeutics to Present at 2024 Aegis Virtual Conference

Chemomab CEO Adi Mor will present at the Aegis Virtual Conference on May 7 at 9:00am ET...

CMMB Twits

Here you can normally see the latest stock twits on CMMB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example